<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - PHENOBARBITAL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>PHENOBARBITAL</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">All forms of epilepsy except typical absence seizures</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                60&#8211;180 mg once daily, dose to be taken at night.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years</strong><br/>
                Initially 1&#8211;1.5 mg/kg twice daily, then increased in steps of 2 mg/kg daily as required; maintenance 2.5&#8211;4 mg/kg 1&#8211;2 times a day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                60&#8211;180 mg once daily, dose to be taken at night.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Status epilepticus</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg/kg (max. per dose 1 g), dose to be administered at a rate not more than 100 mg/minute, injection to be diluted 1 in 10 with water for injections.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years</strong><br/>
                Initially 20 mg/kg, dose to be administered at a rate no faster than 1 mg/kg/minute, then 2.5&#8211;5 mg/kg 1&#8211;2 times a day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 20 mg/kg (max. per dose 1 g), dose to be administered at a rate no faster than 1 mg/kg/minute, then 300 mg twice daily.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>For therapeutic purposes phenobarbital and phenobarbital sodium may be considered equivalent in effect.</p>
            </section>
        
        
        
      </section>




      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>May precipitate coma.</p><p>Avoid in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Use with caution.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Agranulocytosis, allergic skin reactions, ataxia, behavioural disturbances, cholestasis, depression, drowsiness, hallucinations, hepatitis, hyperactivity particularly in the elderly and in children, hypotension, impaired cognition, impaired memory, irritability, lethargy, megaloblastic anaemia (may be treated with folic acid), nystagmus, osteomalacia, paradoxical excitement in adults, respiratory depression, thrombocytopenia,
              </p>
              <p>
                <strong>veryRare:</strong> Antiepileptic Hypersensitivity Syndrome, Stevens-Johnson syndrome, suicidal ideation, toxic epidermal necrolysis,
              </p>
              <p>
                <strong>notKnown:</strong> Hyperkinesia in children,
              </p>
        
        
        
            <section class="overdosageInformation">
                <h3>Emergency treatment of poisoning: active elimination techniques</h3>
              <p>Repeated doses of activated charcoal by mouth <i>enhance</i> the elimination of some drugs after they have been absorbed; repeated doses are given after overdosage with phenobarbital.</p><p>The usual dose of activated charcoal in adults and children over 12 years of age is 50&#8239;g initially then 50&#8239;g every 4 hours. Vomiting should be treated (e.g. with an antiemetic drug) since it may reduce the efficacy of charcoal treatment. In cases of intolerance, the dose may be reduced and the frequency increased (e.g. 25&#8239;g every 2 hours or 12.5&#8239;g every hour) but this may compromise efficacy.</p><p>In children under 12 years of age, activated charcoal is given in a dose of 1&#8239;g/kg (max. 50&#8239;g) every 4 hours; the dose may be reduced and the frequency increased if not tolerated.</p><p>Other techniques intended to enhance the elimination of poisons after absorption are only practicable in hospital and are only suitable for a small number of severely poisoned patients. Moreover, they only apply to a limited number of poisons, for example, haemodialysis for phenobarbital.</p>
            </section>
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Solution for injection must be diluted before intravenous administration.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous injection</i>, dilute to a concentration of 20&#8239;mg/mL with Water for Injections; give over 20 minutes (no faster than 1&#8239;mg/kg/minute).</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>For administration by <i>mouth</i>, tablets may be crushed.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Phenobarbital for preventing seizures</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/phenobarbital-for-preventing-seizures">www.medicinesforchildren.org.uk/phenobarbital-for-preventing-seizures</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Avoid in <xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref>
          </li>
          <li>
            children
          </li>
          <li>
            debilitated
          </li>
          <li>
              <strong>:</strong>
            elderly in adults
          </li>
          <li>
            history of alcohol abuse
          </li>
          <li>
            history of drug abuse
          </li>
          <li>
            respiratory depression (avoid if severe)
          </li>
        </ul>
        <ul>
          <li>
            <p>Consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

          <h3>Therapeutic drug monitoring</h3>
        
            <section class="therapeuticDrugMonitoring">
              <p>Plasma-phenobarbital concentration for optimum response is 15&#8211;40&#8239;mg/litre (60&#8211;180 micromol/litre); however, monitoring the plasma-drug concentration is less useful than with other drugs because tolerance occurs.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
                <h3>Switching between formulations</h3>
              <p>Different formulations of oral preparations may vary in bioavailability. Patients should be maintained on a specific manufacturer's product.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <p>Some hospitals supply <b>alcohol-free</b> formulations of varying phenobarbital strengths.</p>
            </section>
      </section>

      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
              <p>Avoid abrupt withdrawal (dependence with prolonged use).</p>
            </section>
      </section>







      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

        
            <section class="crossSensitivity">
              <p>Antiepileptic hypersensitivity syndrome associated with phenobarbital. See under <xref format="dita" href="#PHP78230" type="bookmark" namespace="/treatment-summaries/epilepsy">Epilepsy</xref> for more information.</p>
            </section>
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of PHENOBARBITAL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral solution,
            oral suspension,
            tablet,
            capsule,

            <div id="PHP76286"><a href="../medicinalForm/PHP76286.html" data-target="#PHP76286" data-action="load">Tablet</a></div>
            <div id="PHP76306"><a href="../medicinalForm/PHP76306.html" data-target="#PHP76306" data-action="load">Oral solution</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
